
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis

Cirrhosis has been associated with decreased responsiveness to several vaccines. In a retrospective study of 26,082 patients with cirrhosis, participants who received three doses of a coronavirus disease 2019 (COVID-19) mRNA vaccine when Delta and Omicron were the predominant variants had an 80.7% reduction in COVID-19 incidence (95% CI 39.2–89.1, $P < 0.001$) compared with matched controls who only received two doses.

Jordan Hindson

Original article: John, B. V. et al. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. *J. Hepatol.* <https://doi.org/10.1016/j.jhep.2022.07.036> (2022)